3Culley CM,Lacy MK,Klutman N,et a1.Moxifloxacin:clinical efficacy and safety[J].Am J Health Syst Pharm,2001,58(5):379-388.
4Stass H,Dalhof A,Kubitza D,et a1.Pharmacokinetics,Safety,and Tolerability of Ascending Single Doses of Moxifloxacin,a New 8-Methoxy Quinolone,Administered to Healthy Subjects[J].Antimic Agents Chemother,1998,42(8):2060-2065.
4Zhanel GG, Noreddin AM. Pharmacokenetics and phamacodynamics of the new fluoroquinolones : focus on respiratory infection [ J]. Curr Opin Parmacol,2001,1:459 -463.
5Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hosptalized patients with pneumonia[ J ]. Stand J Infect Dis, 1998,30 (4) :397 - 404.
6John N. Krieger,Donald E. Riley,Phaik Yeong Cheah,Men Long Liong,Kah Hay Yuen. Epidemiology of prostatitis: new evidence for a world-wide problem[J] 2003,World Journal of Urology(2):70～74
